Abstract:Pulmonary arterial hypertension (PAH) is a malignant pulmonary vascular syndrome characterized by a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, which eventually leads to right heart failure and even death. Although the exact mechanism of PAH is not fully understood, pulmonary vasoconstriction, vascular remodeling, immune and inflammatory responses, and thrombosis are thought to be involved in the development and progression of PAH. In the era of non-targeted agents, PAH had a very dismal prognosis with a median survival time of only 2.8 years. With the deep understanding of the pathophysiological mechanism of PAH as well as advances in drug research, PAH-specific therapeutic drugs have developed rapidly in the past 30 years, but they primarily focus on the three classical signaling pathways, namely the endothelin pathway, nitric oxide pathway, and prostacyclin pathway. These drugs dramatically improved pulmonary hemodynamics, cardiac function, exercise tolerance, quality of life, and prognosis in PAH patients, but could only reduce pulmonary arterial pressure and right ventricular afterload to a limited extent. Current targeted agents delay the progression of PAH but cannot fundamentally reverse pulmonary vascular remodeling. Through unremitting efforts, new therapeutic drugs such as sotatercept have emerged, injecting new vitality into this field. This review comprehensively summarizes the general treatments for PAH, including inotropes and vasopressors, diuretics, anticoagulants, general vasodilators, and anemia management. Additionally, this review elaborates the pharmacological properties and recent research progress of twelve specific drugs targeting three classical signaling pathways, as well as dual-, sequential triple-, and initial triple-therapy strategies based on the aforementioned targeted agents. More crucially, the search for novel therapeutic targets for PAH has never stopped, with great progress in recent years, and this review outlines the potential PAH therapeutic agents currently in the exploratory stage to provide new directions for the treatment of PAH and improve the long-term prognosis of PAH patients.

MicroRNAs and their regulators: Potential therapeutic targets in pulmonary arterial hypertension

The Role of TGF-β or BMPR2 Signaling Pathway-Related Mirna in Pulmonary Arterial Hypertension and Systemic Sclerosis

Epigenetic Regulation and Its Therapeutic Potential in Pulmonary Hypertension

Regulatory role of autophagy in development of pulmonary artery hypertension

MicroRNA‐483 Amelioration of Experimental Pulmonary Hypertension

Recent research progress of microRNAs in hypertension pathogenesis, with a focus on the roles of miRNAs in pulmonary arterial hypertension

Non-Coding RNA Networks in Pulmonary Arterial Hypertension

microRNA-637/661 ameliorate hypoxic-induced pulmonary arterial hypertension by targeting TRIM29 signaling pathway

Micro-RNA Analysis in Pulmonary Arterial Hypertension

Differential Expression of Microrna in the Lungs of Rats with Pulmonary Arterial Hypertension

MicroRNA-27b plays a role in pulmonary arterial hypertension by modulating peroxisome proliferator-activated receptor γ dependent Hsp90-eNOS signaling and nitric oxide production.

Mir-145: A Role in the Development of Pulmonary Arterial Hypertension

Bioactivities and mechanisms of natural medicines in the management of pulmonary arterial hypertension

Prediction of Target Genes for Mir-140-5p in Pulmonary Arterial Hypertension Using Bioinformatics Methods

Mechanisms Contributing to the Dysregulation of miRNA-124 in Pulmonary Hypertension

Molecular Characterization and Elucidation of Pathways to Identify Novel Therapeutic Targets in Pulmonary Arterial Hypertension

Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs

miR‐30d Attenuates Pulmonary Arterial Hypertension via Targeting MTDH and PDE5A and Modulates the Beneficial Effect of Sildenafil

miR-143 Activation Regulates Smooth Muscle and Endothelial Cell Crosstalk in Pulmonary Arterial Hypertension

Advances in the targeted therapy for pulmonary arterial hypertension

RNA m6A methylation and regulatory proteins in pulmonary arterial hypertension